GLP-1 receptor agonist ameliorates experimental lung fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease. This disease is characterized by an excessive accumulation of extracellular matrix deposition that modify normal lung physiology. Up to date, there are not efficient therapeutic tools to fight IPF. Glucagon-like p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fandiño, Juan, Toba, Laura, González-Matías, Lucas C., Diz-Chaves, Yolanda, Mallo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581713/
https://www.ncbi.nlm.nih.gov/pubmed/33093510
http://dx.doi.org/10.1038/s41598-020-74912-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581713/
https://www.ncbi.nlm.nih.gov/pubmed/33093510
http://dx.doi.org/10.1038/s41598-020-74912-1

Ejemplares similares